CO5160265A1 - Esteres aminoacidos de ribavirina y composiciones farmaceuticas que los contienen . - Google Patents

Esteres aminoacidos de ribavirina y composiciones farmaceuticas que los contienen .

Info

Publication number
CO5160265A1
CO5160265A1 CO99065259A CO99065259A CO5160265A1 CO 5160265 A1 CO5160265 A1 CO 5160265A1 CO 99065259 A CO99065259 A CO 99065259A CO 99065259 A CO99065259 A CO 99065259A CO 5160265 A1 CO5160265 A1 CO 5160265A1
Authority
CO
Colombia
Prior art keywords
aminoacidos
ribavirina
esteres
contain
pharmaceutical compositions
Prior art date
Application number
CO99065259A
Other languages
English (en)
Inventor
K Ganguly Ashit
Mccormick Jinping
Raymond G Lovey
Frank Bennett
K Saksena Anil
M Girijavallab Viyyoor
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO5160265A1 publication Critical patent/CO5160265A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056Triazole or tetrazole radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para tratar un paciente que padece de una infección por hepatitis C crónica, a los efectos de erradicar el HCV - RNA detectable, que comprende una terapia combinatoria, la cual emplea una cantidad terapéuticamente efectiva de un derivado de ribavirina de la fórmula I y una cantidad terapéuticamente efectiva de interferón alfa, durante un lapso que varía entre 20 y 80 semanas.
CO99065259A 1998-10-16 1999-10-14 Esteres aminoacidos de ribavirina y composiciones farmaceuticas que los contienen . CO5160265A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17405998A 1998-10-16 1998-10-16
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon

Publications (1)

Publication Number Publication Date
CO5160265A1 true CO5160265A1 (es) 2002-05-30

Family

ID=22634639

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99065259A CO5160265A1 (es) 1998-10-16 1999-10-14 Esteres aminoacidos de ribavirina y composiciones farmaceuticas que los contienen .

Country Status (9)

Country Link
US (1) US6277830B1 (es)
EP (1) EP1121370A1 (es)
KR (1) KR20010080098A (es)
AR (1) AR021226A1 (es)
AU (1) AU1197600A (es)
CO (1) CO5160265A1 (es)
PE (1) PE20001109A1 (es)
WO (1) WO2000023455A1 (es)
ZA (1) ZA200102917B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800616B2 (en) * 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6403564B1 (en) * 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP1244356A4 (en) * 1999-12-23 2003-03-19 Icn Pharmaceuticals COMPOSITIONS AND METHODS RELATING TO NUCLEOSIDES-L, NUCLEOTIDES-L AND THEIR ANALOGS
AU2001249120A1 (en) * 2000-03-09 2001-09-17 Schering Corporation Hiv immune adjuvant therapy
WO2001081359A1 (en) * 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6510314B1 (en) 2000-09-08 2003-01-21 Visteon Global Technologies, Inc. Mixer circuit with output stage for implementation on integrated circuit
EP1326594A2 (en) * 2000-10-18 2003-07-16 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
US6673775B2 (en) * 2001-04-18 2004-01-06 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP1404694A1 (en) * 2001-06-21 2004-04-07 Glaxo Group Limited Nucleoside compounds in hcv
EP1461067A1 (en) * 2001-12-07 2004-09-29 Intermune, Inc. Compositions and method for treating hepatitis virus infection
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003248748A1 (en) * 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US20040106785A1 (en) * 2002-07-25 2004-06-03 Micrologix Biotech Inc. Inhibitors of RNA dependent RNA polymerase and uses thereof
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
CA2508656A1 (en) * 2002-12-10 2004-06-24 F.Hoffmann-La Roche Ag Antiviral nucleoside derivatives
CA2509687C (en) 2002-12-12 2012-08-14 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
EP1599171A2 (en) * 2003-02-28 2005-11-30 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
CN1791599A (zh) * 2003-05-21 2006-06-21 贝林格尔.英格海姆国际有限公司 丙型肝炎抑制剂化合物
CN1835765A (zh) * 2003-08-13 2006-09-20 霍华德·J·史密斯及同仁控股有限公司 治疗病毒感染的方法
CA2537849A1 (en) * 2003-09-11 2005-03-17 F. Hoffmann-La Roche Ag Process for preparing antiviral nucleoside derivatives
CA2537878A1 (en) * 2003-09-11 2005-03-17 F. Hoffmann-La Roche Ag Polymorphic nucleoside compounds
EP2407470A3 (en) 2003-10-14 2015-06-10 F. Hoffmann-La Roche Ltd. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US7410979B2 (en) * 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
WO2005123113A2 (en) * 2004-06-14 2005-12-29 Intermune, Inc. Interferon compositions and methods of use thereof
CA2571675A1 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (en) * 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
JP2008540425A (ja) * 2005-05-02 2008-11-20 ライジェル ファーマシューティカルズ, インコーポレイテッド 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用
BRPI0613962A2 (pt) 2005-07-25 2009-03-24 Intermune Inc inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
JP5254033B2 (ja) 2005-12-23 2013-08-07 イデニク プハルマセウティカルス,インコーポレイテッド 分岐型ヌクレオシドを調製するための合成中間体の製造方法
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. C형 간염 바이러스 복제의 신규 억제제
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
JP2010510171A (ja) * 2006-08-21 2010-04-02 ユナイテッド セラピューティクス コーポレーション ウイルス感染症の治療のための併用療法
WO2008067002A2 (en) * 2006-09-11 2008-06-05 Southern Research Institute Azole nucleosides and use as inhibitors of rna and dna varial polymerases
WO2008052722A2 (en) * 2006-11-02 2008-05-08 Heidelberg Pharma Ag Use of ribavirin-conjugates as an anti-viral drug
NZ581606A (en) 2007-05-03 2012-06-29 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
AU2008251425A1 (en) * 2007-05-10 2008-11-20 Array Biopharma, Inc. Novel peptide inhibitors of hepatitis C virus replication
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
CN102216321A (zh) 2008-10-15 2011-10-12 因特蒙公司 治疗性抗病毒肽
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
CN102448458B (zh) 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
CN102741270B (zh) 2009-09-28 2015-07-22 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
CA2813093A1 (en) 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
SG11201402899TA (en) 2011-12-06 2014-07-30 Univ Leland Stanford Junior Methods and compositions for treating viral diseases
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
GB1482736A (en) 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US4925930A (en) 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
DE69324671D1 (de) * 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
JP2001503767A (ja) 1996-11-12 2001-03-21 メディヴィル・アクチボラグ ヌクレオシド

Also Published As

Publication number Publication date
AU1197600A (en) 2000-05-08
WO2000023455A1 (en) 2000-04-27
KR20010080098A (ko) 2001-08-22
PE20001109A1 (es) 2000-10-28
US6277830B1 (en) 2001-08-21
EP1121370A1 (en) 2001-08-08
AR021226A1 (es) 2002-07-03
WO2000023455A9 (en) 2000-08-24
ZA200102917B (en) 2002-07-09

Similar Documents

Publication Publication Date Title
CO5160265A1 (es) Esteres aminoacidos de ribavirina y composiciones farmaceuticas que los contienen .
BR9812484A (pt) Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c
ES2172288T3 (es) Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
ES2196303T3 (es) Administracion de nicotina por el colon para tratar enfermedades intestinales inflamatorias.
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
CY1111153T1 (el) Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
ES2192839T3 (es) Timosina beta 4 oxidada.
DK0696456T3 (da) Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme
BR9915546A (pt) Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica
GT199900015A (es) Procedimiento para tratar la insuficiencia cardiaca
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
PT998287E (pt) Utilizacao de levobupivacaina
GB0130677D0 (en) Medicaments and novel compounds
ES2164447T3 (es) Procedimiento de inhibicion de resorcion del hueso.
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
ATE81004T1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
SE0004101D0 (sv) New use
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
ES2046246T3 (es) Composicion terapeutica para combatir el sida.
SE0004827D0 (sv) Therapeutic compounds